LAS VEGAS, June 10, 2026 /PRNewswire/ — Hyperscale Data, Inc. (NYSE American: GPUS), an artificial intelligence (“AI”) data center company anchored by Bitcoin (“Hyperscale Data” or the “Company”), today announced the final results of its cash tender offer (the “Offer”) to repurchase up to 23,809,523 shares of its Class A common stock, par value $0.001 per share (“Class A common stock”), at a fixed purchase price of $0.21 per share, for an aggregate purchase price of up to approximately $5.0 million. The Offer expired at one minute after 11:59 p.m. Eastern Time on June 8, 2026.

Based on the final count by Computershare Trust Company, N.A., the depositary for the Offer (the “Depositary”), a total of 8,731,574 shares of Class A common stock were validly tendered and not validly withdrawn, which includes shares that were tendered through notice of guaranteed delivery.

In accordance with the terms and conditions of the Offer, the Company accepted for purchase a total of 8,731,574 shares, for an aggregate purchase price of approximately $1.83 million, excluding fees and expenses related to the Offer. The shares purchased represent approximately 1.9% of Hyperscale Data’ outstanding Class A common stock as of May 15, 2026.

The Depositary will promptly pay for all shares accepted for purchase pursuant to the Offer using the Company’s existing cash and cash equivalents and return all other shares tendered and not purchased.

Stockholders with questions about the Offer may contact Georgeson LLC, the information agent for the Offer at (877) 514-4861.

About Hyperscale Data, Inc.

Through its wholly owned subsidiary Sentinum, Inc., Hyperscale Data owns and operates a data center at which it mines digital assets and offers colocation and hosting services for the emerging AI ecosystems and other industries. Hyperscale Data’s other wholly owned subsidiary, Ault Capital Group, Inc. (“ACG”), is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact.

Hyperscale Data currently expects the divestiture of ACG (the “Divestiture”) to occur in the second quarter of 2027. Upon the occurrence of the Divestiture, the Company would be an owner and operator of data centers to support high-performance computing services, as well as a holder of the digital assets. Until the Divestiture occurs, the Company will continue to provide, through ACG and its wholly and majority-owned subsidiaries and strategic investments, mission-critical products that support a diverse range of industries, including an AI software platform, equipment rental services, defense/aerospace, industrial, automotive and hotel operations. In addition, ACG is actively engaged in private credit and structured finance through Ault Lending, LLC, a licensed lending subsidiary. Hyperscale Data’s headquarters are located at 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141.

On December 23, 2024, the Company issued one million (1,000,000) shares of a newly designated Series F Exchangeable Preferred Stock (the “Series F Preferred Stock”) to all common stockholders and holders of the Series C Preferred Stock on an as-converted basis. The Divestiture will occur through the voluntary exchange of the Series F Preferred Stock for shares of Class A Common Stock and Class B Common Stock of ACG (collectively, the “ACG Shares”). The Company reminds its stockholders that only those holders of the Series F Preferred Stock who agree to surrender such shares, and do not properly withdraw such surrender, in the exchange offer through which the Divestiture will occur, will be entitled to receive the ACG Shares and consequently be shareholders of ACG upon the occurrence of the Divestiture.

Forward-Looking Statements

This press release contains “forward-looking statements” regarding future events and our future results. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties.

Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events, except as required by law. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company’s website at hyperscaledata.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hyperscale-data-inc-announces-final-results-for-tender-offer-302796339.html

SOURCE Hyperscale Data Inc.

Preclinical studies in disease-relevant models demonstrate the ability of HERVolution’s HERV-targeting platform to control weight gain, reverse type 2 diabetes, and lower “inflammaging” biomarkers

Exclusive license agreement, combined with core company-owned IP, further solidifies the potential of IPT-001 in metabolic disease and longevity

COPENHAGEN, Denmark and NEW YORK, June 10, 2026 /PRNewswire/ — HERVolution Therapeutics ApS, a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for metabolic diseases, longevity, and oncology, today announced preclinical proof-of-concept for its proprietary technology in metabolic disease, presented at the American Diabetes Association 2026 Scientific Sessions, held June 5-8, 2026, in New Orleans. The company concurrently announced an exclusive license agreement with the University of Copenhagen (UCPH) covering the commercialization of HERV-targeting technology for controlling weight gain.

Studies conducted in collaboration with researchers at UCPH successfully applied HERVolution’s proprietary technology to engage endogenous retroviral targets in preclinical models of weight gain, demonstrating the ability of an immune therapy to control weight gain in a high fat diet plus underlying metabolic disease context.

In parallel, HERVolution and UCPH have entered into an exclusive license agreement as an outcome of their research collaboration. Under the agreement, HERVolution receives exclusive rights to develop, manufacture and commercialize products in the licensed field.

Together, the preclinical results and the licensing framework establish a foundation for HERVolution to advance HERV-targeting immunotherapies for metabolic diseases as a core therapeutic pillar alongside its oncology program, consistent with the Company’s broader ambition to apply its HERV-targeting platform across oncology, metabolic diseases, and ultimately longevity.

“These preclinical results are an important validation of our dark genome-derived technology beyond oncology. Demonstrating that our platform has broad utility to engage endogenous retroviral targets in metabolic disease models opens a meaningful direction for the Company,” said J. Robert Coleman, PhD, MBA, CEO of HERVolution Therapeutics. “The license agreement with the University of Copenhagen, combined with our solely owned, proprietary IP provides a strong foundational framework to advance a new class of off-the-shelf, HERV-targeting immunotherapies for some of the world’s most prevalent conditions.”

About HERVolution Therapeutics

HERVolution Therapeutics is a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for oncology, metabolic diseases, and longevity. HERVs are ancient viral sequences embedded in the human genome that become reactivated in cancer and other diseases of aging. By directing the immune system against HERV-derived antigens, HERVolution aims to deliver a new class of senolytic therapies across multiple indications where HERV reactivation and cellular senescence contribute to disease biology. The Company’s lead program, IPT-001, is advancing toward first-in-human studies in oncology and metabolic disease. For more information, visit hervolutiontx.com. Follow us on LinkedIn and X.

About the University of Copenhagen
Founded in 1479, the University of Copenhagen (UCPH) is one of the leading research universities in Europe, with a strong tradition in biomedical and translational research. UCPH actively supports the translation of academic discoveries of therapeutic potential into clinical development through partnerships with industry.

Media Contact

HERVolution Therapeutics ApS
HERVolution Therapeutics
communications@hervolutiontx.com
www.hervolutiontx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/hervolution-therapeutics-demonstrates-preclinical-proof-of-concept-for-insulin-sensitization-immune-therapy-in-metabolic-disease-and-announces-exclusive-license-agreement-with-the-university-of-copenhagen-302795590.html

SOURCE HERVolution Therapeutics

New platform investments help insurers scale internationally while supporting participation in the Lloyd’s specialty insurance marketplace

LONDON, June 10, 2026 /PRNewswire/ — Duck Creek, the intelligent core of insurance, today announced its global expansion strategy and expanded support for insurers operating across international markets at London ENGAGE, its annual conference for insurance leaders across the UK and European markets. Building on its commitment to help carriers scale globally, Duck Creek introduced enhancements to its Multi-Country Layer architecture and announced a strategic investment to support the London Market, including plans to pursue Lloyd’s market certification.

As the world’s leading marketplace for specialty and multinational risk, the London Market depends on complex collaboration among brokers, syndicates, carriers, cover holders and partners, supported by highly specialised process flows, extensive data exchange and rigorous operational controls. Duck Creek is investing in capabilities designed to support participation in the London Market and plans to pursue Lloyd’s market certification as part of its broader strategy to serve the needs of insurers operating across this global insurance ecosystem.

Complementing these London Market capabilities is the continued expansion of Duck Creek’s Multi-Country Layer (MCL) hierarchy design, a foundational capability that enables insurers to manage global and regional operations through a unified framework. Generally available today, MCL spans Duck Creek Policy, Billing, Claims and Clarity, with expansion underway across digital solutions. Designed for multinational insurers, MCL provides a common operational framework that helps carriers enter new markets faster, reuse existing configurations, and maintain consistency across global operations while meeting local market requirements.

“Duck Creek has long been a leader in core insurance technology, helping insurers modernise policy administration, streamline operations, and adapt more quickly to changing market demands,” said Hardeep Gulati, Chief Executive Officer at Duck Creek. “Our investment in London Market capabilities extends that leadership into one of the world’s most sophisticated specialty insurance ecosystems. By expanding Duck Creek’s intelligent core systems to support London Market operations and connectivity requirements, we enable insurers to manage the full policy lifecycle more efficiently, improve operational agility, and build on the investments, partnerships, and market infrastructure they already depend upon.”

The company is focused on allowing insurers to more easily access and operate across international markets while reducing operational complexity by improving efficiency across the end-to-end insurance lifecycle. By combining cloud-native architecture, agentic intelligence and deep insurance expertise, Duck Creek helps carriers operate more efficiently across markets while remaining responsive to local requirements.

“Global growth is no longer just about entering new markets; it is about doing so with speed, consistency and control,” said Jose Lazares, Chief Product Officer at Duck Creek. “Duck Creek’s Multi-Country Layer gives insurers a reusable operating model for scaling across regions while adapting to local market requirements. Our investment in London Market capabilities strengthens that foundation, extending Duck Creek’s leadership in specialty policy underwriting into one of the world’s most complex insurance ecosystems. Together, these capabilities help carriers reduce operational complexity, strengthen underwriting discipline and pursue more profitable growth across markets.”

The MCL hierarchy provides a flexible and structured approach to managing multi-country configurations, enabling insurers to:

Reuse components across regions, avoiding duplicative set-up;Reduce implementation timelines with preconfigured, out-of-the-box structures; andAccelerate entry into new markets while maintaining governance and consistency.

Duck Creek currently supports insurers operating across major global markets, including North America, the United Kingdom and Ireland, India, Australia, New Zealand and more. Continued investment will expand support across additional European and Asia-Pacific markets.

By combining a modernised configuration model, intelligent automation and expanded support for global insurance ecosystems, Duck Creek empowers carriers to:

Execute international growth strategies without duplicating effort;Adapt quickly to local regulatory requirements; andReduce operational complexity across multi-country deployments.

About Duck Creek 

Duck Creek is the intelligent core that leading insurers choose to build on. Purpose-built for property and casualty (P&C) and general insurance, Duck Creek unifies the full insurance lifecycle on a single platform with one data foundation. As an agentic platform, it connects intelligence across underwriting, policy, billing, claims, and payments of workflows where decisions are made and compliance is non-negotiable. Duck Creek enables carriers to launch products faster, adapt quickly to change, and grow with precision and confidence. Solutions are available individually or as a full suite via Duck Creek OnDemand. Visit www.duckcreek.com and follow Duck Creek on LinkedIn and X. 

Media Contacts: 
Marianne Dempsey / Tara Stred 
duckcreek@threeringsinc.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/duck-creek-expands-global-platform-strategy-with-multi-country-layer-enhancements-and-commitment-to-support-the-london-market-302796005.html